Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells.
Identifieur interne : 002130 ( PubMed/Checkpoint ); précédent : 002129; suivant : 002131Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells.
Auteurs : Anna De Lang [Pays-Bas] ; Albert D M E. Osterhaus ; Bart L. HaagmansSource :
- Virology [ 0042-6822 ] ; 2006.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (pharmacologie), Cellules Vero (), Cellules Vero (métabolisme), Facteurs temps, Interféron gamma (pharmacologie), Interleukine-4 (pharmacologie), Relation dose-effet des médicaments, Récepteurs viraux (), Récepteurs viraux (métabolisme), Régulation négative, Réplication virale (), Syndrome respiratoire aigu sévère (virologie), Virus du SRAS (physiologie).
- MESH :
- métabolisme : Cellules Vero, Récepteurs viraux.
- pharmacologie : Antiviraux, Interféron gamma, Interleukine-4.
- physiologie : Virus du SRAS.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Cellules Vero, Facteurs temps, Relation dose-effet des médicaments, Récepteurs viraux, Régulation négative, Réplication virale.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Chlorocebus aethiops, Dose-Response Relationship, Drug, Down-Regulation, Interferon-gamma (pharmacology), Interleukin-4 (pharmacology), Receptors, Virus (drug effects), Receptors, Virus (metabolism), SARS Virus (physiology), Severe Acute Respiratory Syndrome (virology), Time Factors, Vero Cells (drug effects), Vero Cells (metabolism), Virus Replication (drug effects).
- MESH :
- chemical , drug effects : Receptors, Virus.
- chemical , metabolism : Receptors, Virus.
- chemical , pharmacology : Antiviral Agents, Interferon-gamma, Interleukin-4.
- drug effects : Vero Cells, Virus Replication.
- metabolism : Vero Cells.
- physiology : SARS Virus.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Chlorocebus aethiops, Dose-Response Relationship, Drug, Down-Regulation, Time Factors.
Abstract
Interferons (IFNs) inhibit severe acute respiratory syndrome coronavirus (SARS-CoV) replication and might be valuable for SARS treatment. In this study, we demonstrate that treatment of Vero E6 cells with interleukin-4 (IL-4) decreased the susceptibility of these cells to SARS-CoV infection. In contrast to IFNs, IL-4 did not show antiviral activity when administered immediately after SARS-CoV infection, suggesting that IL-4 acts early during the SARS-CoV replication cycle. Indeed, binding of recombinant SARS-CoV spike protein to Vero E6 cells was diminished on cells treated with IL-4, but also on cells exposed to IFN-gamma. Consistent with these observations, IL-4 and IFN-gamma downregulated cell surface expression of angiotensin-converting enzyme 2 (ACE2), the SARS-CoV receptor. Besides diminished ACE2 cell surface expression, ACE2 mRNA levels were also decreased after treatment with these cytokines. These findings suggest that IL-4 and IFN-gamma inhibit SARS-CoV replication partly through downregulation of ACE2.
DOI: 10.1016/j.virol.2006.06.011
PubMed: 16860835
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:16860835Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells.</title><author><name sortKey="De Lang, Anna" sort="De Lang, Anna" uniqKey="De Lang A" first="Anna" last="De Lang">Anna De Lang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Erasmus Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Virology, Erasmus Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam</wicri:regionArea><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D M E" last="Osterhaus">Albert D M E. Osterhaus</name></author><author><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L" last="Haagmans">Bart L. Haagmans</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16860835</idno><idno type="pmid">16860835</idno><idno type="doi">10.1016/j.virol.2006.06.011</idno><idno type="wicri:Area/PubMed/Corpus">002156</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002156</idno><idno type="wicri:Area/PubMed/Curation">002156</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002156</idno><idno type="wicri:Area/PubMed/Checkpoint">002130</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002130</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells.</title><author><name sortKey="De Lang, Anna" sort="De Lang, Anna" uniqKey="De Lang A" first="Anna" last="De Lang">Anna De Lang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Erasmus Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Virology, Erasmus Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam</wicri:regionArea><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D M E" last="Osterhaus">Albert D M E. Osterhaus</name></author><author><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L" last="Haagmans">Bart L. Haagmans</name></author></analytic><series><title level="j">Virology</title><idno type="ISSN">0042-6822</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Chlorocebus aethiops</term><term>Dose-Response Relationship, Drug</term><term>Down-Regulation</term><term>Interferon-gamma (pharmacology)</term><term>Interleukin-4 (pharmacology)</term><term>Receptors, Virus (drug effects)</term><term>Receptors, Virus (metabolism)</term><term>SARS Virus (physiology)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Time Factors</term><term>Vero Cells (drug effects)</term><term>Vero Cells (metabolism)</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (pharmacologie)</term><term>Cellules Vero ()</term><term>Cellules Vero (métabolisme)</term><term>Facteurs temps</term><term>Interféron gamma (pharmacologie)</term><term>Interleukine-4 (pharmacologie)</term><term>Relation dose-effet des médicaments</term><term>Récepteurs viraux ()</term><term>Récepteurs viraux (métabolisme)</term><term>Régulation négative</term><term>Réplication virale ()</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Virus du SRAS (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Virus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Virus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-gamma</term><term>Interleukin-4</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Vero Cells</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Vero Cells</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cellules Vero</term><term>Récepteurs viraux</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Interféron gamma</term><term>Interleukine-4</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Dose-Response Relationship, Drug</term><term>Down-Regulation</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Facteurs temps</term><term>Relation dose-effet des médicaments</term><term>Récepteurs viraux</term><term>Régulation négative</term><term>Réplication virale</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Interferons (IFNs) inhibit severe acute respiratory syndrome coronavirus (SARS-CoV) replication and might be valuable for SARS treatment. In this study, we demonstrate that treatment of Vero E6 cells with interleukin-4 (IL-4) decreased the susceptibility of these cells to SARS-CoV infection. In contrast to IFNs, IL-4 did not show antiviral activity when administered immediately after SARS-CoV infection, suggesting that IL-4 acts early during the SARS-CoV replication cycle. Indeed, binding of recombinant SARS-CoV spike protein to Vero E6 cells was diminished on cells treated with IL-4, but also on cells exposed to IFN-gamma. Consistent with these observations, IL-4 and IFN-gamma downregulated cell surface expression of angiotensin-converting enzyme 2 (ACE2), the SARS-CoV receptor. Besides diminished ACE2 cell surface expression, ACE2 mRNA levels were also decreased after treatment with these cytokines. These findings suggest that IL-4 and IFN-gamma inhibit SARS-CoV replication partly through downregulation of ACE2.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16860835</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0042-6822</ISSN><JournalIssue CitedMedium="Print"><Volume>353</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Virology</Title><ISOAbbreviation>Virology</ISOAbbreviation></Journal><ArticleTitle>Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells.</ArticleTitle><Pagination><MedlinePgn>474-81</MedlinePgn></Pagination><Abstract><AbstractText>Interferons (IFNs) inhibit severe acute respiratory syndrome coronavirus (SARS-CoV) replication and might be valuable for SARS treatment. In this study, we demonstrate that treatment of Vero E6 cells with interleukin-4 (IL-4) decreased the susceptibility of these cells to SARS-CoV infection. In contrast to IFNs, IL-4 did not show antiviral activity when administered immediately after SARS-CoV infection, suggesting that IL-4 acts early during the SARS-CoV replication cycle. Indeed, binding of recombinant SARS-CoV spike protein to Vero E6 cells was diminished on cells treated with IL-4, but also on cells exposed to IFN-gamma. Consistent with these observations, IL-4 and IFN-gamma downregulated cell surface expression of angiotensin-converting enzyme 2 (ACE2), the SARS-CoV receptor. Besides diminished ACE2 cell surface expression, ACE2 mRNA levels were also decreased after treatment with these cytokines. These findings suggest that IL-4 and IFN-gamma inhibit SARS-CoV replication partly through downregulation of ACE2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Lang</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Virology, Erasmus Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osterhaus</LastName><ForeName>Albert D M E</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Haagmans</LastName><ForeName>Bart L</ForeName><Initials>BL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Virology</MedlineTA><NlmUniqueID>0110674</NlmUniqueID><ISSNLinking>0042-6822</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011991">Receptors, Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011991" MajorTopicYN="N">Receptors, Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>05</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>06</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>11</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16860835</ArticleId><ArticleId IdType="pii">S0042-6822(06)00405-3</ArticleId><ArticleId IdType="doi">10.1016/j.virol.2006.06.011</ArticleId><ArticleId IdType="pmc">PMC7111939</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2003 Jul 26;362(9380):263-70</Citation><ArticleIdList><ArticleId IdType="pubmed">12892955</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Virol. 2005 Feb;75(2):185-94</Citation><ArticleIdList><ArticleId IdType="pubmed">15602737</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2001 Feb;75(3):1205-10</Citation><ArticleIdList><ArticleId IdType="pubmed">11152493</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1990 Feb 1;144(3):960-3</Citation><ArticleIdList><ArticleId IdType="pubmed">1688593</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Aug;78(15):8047-58</Citation><ArticleIdList><ArticleId IdType="pubmed">15254176</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1996 Oct;70(10):7103-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8794356</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2004 Mar 20;363(9413):938-47</Citation><ArticleIdList><ArticleId IdType="pubmed">15043961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2005 Jan 28;326(4):905-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15607755</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2005 Aug;11(8):875-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16007097</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2004 Mar;10(3):290-3</Citation><ArticleIdList><ArticleId IdType="pubmed">14981511</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1773-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12781536</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1996 Aug;70(8):5230-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8764032</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>BMC Med. 2004 May 19;2:19</Citation><ArticleIdList><ArticleId IdType="pubmed">15151696</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>FEBS Lett. 2002 Dec 4;532(1-2):107-10</Citation><ArticleIdList><ArticleId IdType="pubmed">12459472</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Mol Biol. 2003 Aug 29;331(5):991-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">12927536</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2006 Jan 30;24(5):652-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16214268</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Jul 26;362(9380):293-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12892961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2004 Nov 10;329(1):11-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15476870</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 May 31;102(22):7988-93</Citation><ArticleIdList><ArticleId IdType="pubmed">15897467</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hypertension. 2004 May;43(5):970-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15007027</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2002 Jun 20;417(6891):822-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12075344</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hypertension. 2003 Mar;41(3):392-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12623933</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Dec;79(23):14614-21</Citation><ArticleIdList><ArticleId IdType="pubmed">16282461</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2002 Apr 26;277(17):14838-43</Citation><ArticleIdList><ArticleId IdType="pubmed">11815627</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2003 Nov 1;171(9):4708-16</Citation><ArticleIdList><ArticleId IdType="pubmed">14568946</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1989 Mar;63(3):1354-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2536838</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cytokine. 2002 Jan 7;17(1):28-35</Citation><ArticleIdList><ArticleId IdType="pubmed">11886168</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Pathol. 2004 Jun;203(2):631-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Circ Res. 2000 Sep 1;87(5):E1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10969042</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2005 Jul 7;436(7047):112-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16001071</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2002 Nov 28;347(22):1795-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12456857</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Methods. 2001 Dec;25(4):402-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Exp Immunol. 2004 Apr;136(1):95-103</Citation><ArticleIdList><ArticleId IdType="pubmed">15030519</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hypertension. 2003 Oct;42(4):749-53</Citation><ArticleIdList><ArticleId IdType="pubmed">12874086</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Pays-Bas</li></country></list><tree><noCountry><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L" last="Haagmans">Bart L. Haagmans</name><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D M E" last="Osterhaus">Albert D M E. Osterhaus</name></noCountry><country name="Pays-Bas"><noRegion><name sortKey="De Lang, Anna" sort="De Lang, Anna" uniqKey="De Lang A" first="Anna" last="De Lang">Anna De Lang</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002130 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002130 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:16860835
|texte= Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:16860835" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |